Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma

Annals of Surgery

Volumn 255, Issue 4, 2012, Pages 771-776

  Bastiaannet, Esther ^a   Uyl De Groot, Carin A ^b   Brouwers, Adrienne H ^b   Van Der Jagt, Eric J ^a   Hoekstra, Otto S ^c   Oyen, Wim ^d   Verzijlbergen, Fred ^e   Van Ooijen, Bart ^f   Thompson, John F ^g   Hoekstra, Harald J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Department of Epidemiology ^*  (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ST ANTONIUS HOSPITAL   (Netherlands)

^f MEANDER MEDICAL CENTER   (Netherlands)

^g MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; FEMALE; FLUORODEOXYGLUCOSE F18; HOSPITAL COSTS; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEOPLASM STAGING; NETHERLANDS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS;

EID: 84863403429     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31824a5742     Document Type: Article

References (17)

1. Giblin AV, Thomas JM. Incidence, mortality, and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg. 2007;60:32-40. (Pubitemid 44763123)
2. Prichard RS, Hill AD, Skehan SJ, et al. Positron emission tomography for staging and management of malignant melanoma. Br J Surg. 2002;89:389-396. (Pubitemid 34595501)
3. Mijnhout GS, Hoekstra OS, van TulderMW, et al. Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 2001;91:1530-1542. (Pubitemid 32319265)
4. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355: 1307-1317. (Pubitemid 44465459)
5. Havenga K, Cobben DC, Oyen WJ, et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol. 2003;29:662-664. (Pubitemid 37236287)
6. Bastiaannet E, Wobbes T, Hoekstra OS, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol. 2009;27: 4774-4780.
7. Boyle P, Maisonneuve P, Dore JF. Epidemiology of malignant melanoma. Br Med Bull. 1995;51:523-547.
8. Lee YT. Malignant melanoma: pattern of metastasis. CA Cancer J Clin. 1980;30:137-142. (Pubitemid 10007466)
9. Stas M, Stroobants S, Dupont P, et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res. 2002;12:479-490. (Pubitemid 35264725)
10. Brady MS, Akhurst T, Spanknebel K, et al. Utility of preoperative (18)f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol. 2006;13:525-532.
11. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer. 2000;89:1019-1025.
12. Mansour AA, III, Kelley MC, Hatmaker AR, et al. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging. Ann Surg Oncol. 2010;17:1144-1151.
13. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332. (Pubitemid 38552885)
14. Ollila DW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol. 2006;7:919-924. (Pubitemid 44615951)
15. Valk PE, Pounds TR, Tesar RD, et al. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol. 1996;23:737-743. (Pubitemid 26342476)
16. Gulec SA, Faries MB, Lee CC, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med. 2003;28:961-965. (Pubitemid 38281828)
17. Mottaghy FM, Sunderkotter C, Schubert R, et al. Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. Eur J Nucl MedMol Imaging. 2007;34:1355-1364. (Pubitemid 47312575)